New hope for young hodgkin lymphoma patients: trial aims to boost cure rates, cut radiation
NCT ID NCT06563245
Summary
This study is testing a new combination of cancer drugs for children, teens, and young adults (ages 2-35) newly diagnosed with classical Hodgkin lymphoma. The main goal is to improve the rate of early, complete response to treatment, which could allow more patients to avoid radiation therapy and its long-term side effects. Researchers aim to maintain high survival rates while reducing the need for radiation by using a targeted drug called brentuximab vedotin and adjusting treatment based on early PET scan results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Children's Medical Center
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.